Free Trial
NASDAQ:AQST

Aquestive Therapeutics (AQST) Stock Price, News & Analysis

Aquestive Therapeutics logo
$3.68 +0.28 (+8.24%)
Closing price 04:00 PM Eastern
Extended Trading
$3.64 -0.04 (-1.09%)
As of 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Aquestive Therapeutics Stock (NASDAQ:AQST)

Key Stats

Today's Range
$3.39
$3.69
50-Day Range
$2.22
$3.58
52-Week Range
$2.12
$5.80
Volume
1.27 million shs
Average Volume
1.49 million shs
Market Capitalization
$365.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.14
Consensus Rating
Buy

Company Overview

Aquestive Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

AQST MarketRank™: 

Aquestive Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 807th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aquestive Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Aquestive Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aquestive Therapeutics are expected to decrease in the coming year, from ($0.46) to ($0.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aquestive Therapeutics is -6.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aquestive Therapeutics is -6.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Aquestive Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    13.18% of the float of Aquestive Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aquestive Therapeutics has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Aquestive Therapeutics has recently increased by 7.72%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Aquestive Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aquestive Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.18% of the float of Aquestive Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aquestive Therapeutics has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Aquestive Therapeutics has recently increased by 7.72%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Aquestive Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Aquestive Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    7 people have searched for AQST on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aquestive Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.85% of the stock of Aquestive Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 32.45% of the stock of Aquestive Therapeutics is held by institutions.

  • Read more about Aquestive Therapeutics' insider trading history.
Receive AQST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AQST Stock News Headlines

Aquestive Therapeutics Inc (AQST) - Investing.com
The Pentagon just made a National Security move...
This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.... a consultant who's worked for the likes of J.P. Morgan and Citicorp... into the middle of the Utah desert with a film crew.Why? So he could lead an investigation into a radical new kind of energy that's so abundant, the Dept. of Energy says it could meet America's power needs for the next 2 million years. It's got nothing to do with wind, solar, nuclear, oil or gas.
See More Headlines

AQST Stock Analysis - Frequently Asked Questions

Aquestive Therapeutics' stock was trading at $3.56 at the beginning of 2025. Since then, AQST stock has increased by 3.2% and is now trading at $3.6750.
View the best growth stocks for 2025 here
.

Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced its quarterly earnings data on Monday, May, 12th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.07. The business earned $8.72 million during the quarter, compared to the consensus estimate of $12.23 million.
Read the conference call transcript
.

Aquestive Therapeutics (AQST) raised $60 million in an IPO on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aquestive Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and GE Aerospace (GE).

Company Calendar

Last Earnings
5/12/2025
Today
7/02/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AQST
Fax
N/A
Employees
160
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.14
High Stock Price Target
$17.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+181.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$44.14 million
Net Margins
-100.02%
Pretax Margin
-100.05%

Debt

Sales & Book Value

Annual Sales
$57.56 million
Price / Cash Flow
N/A
Book Value
($0.66) per share
Price / Book
-5.46

Miscellaneous

Free Float
91,531,000
Market Cap
$357.69 million
Optionable
Optionable
Beta
1.97
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:AQST) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners